New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
10:47 EDTHARTHarvard Apparatus says response from FDA meeting 'very favorable'
Harvard Apparatus said in investor presentation slides that its pre-Investigational New Drug meeting with the FDA at the end of January yielded a "very favorable response." The company expects an orphan designation determination by the FDA in Q2. Harvard added that it has approximately two years of capital at current burn rates and no debt. Harvard said that eight patients are using its bioreactor technology with six of those alive at February 2014. The two that did not survive died of unrelated causes, it said. Shares of Harvard Apparatus are up 6%, or 42c, to $7.71 in morning trading.
News For HART From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 25, 2015
08:03 EDTHARTHarvard Apparatus names James McGorry as CEO, effective July 6
Harvard Apparatus Regenerative Technology announced the appointment of James McGorry, MBA, as CEO, effective July 6. McGorry has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since February 2013. HART plans to provide a corporate update on its second quarter financial call in August following a business review by McGorry and the management team.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use